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Abstract
In this Commentary, we echo the conclusions of a recent review titled “The promise of stem cell-derived islet replacement
therapy,” which highlighted recent advances in producing glucose responsive “islets” from stem cells and the benefits of their
use in islet transplant therapy in type 1 diabetes (T1D). The review also outlined the status of clinical islet transplantation and
the challenges that have prevented it from reaching its full therapeutic promise. We agree with the conclusions of the review
and suggest that the identified challenges may be overcome by using the eye anterior chamber as an islet transplant site. We
anticipate that the combination of stem cell-derived islets and intraocular transplant could help this promising T1D therapy
reach full fruition.
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We read with great interest the review by D. Melton recently
published in Diabetologia journal, titled “The promise of
stem cell-derived islet replacement therapy.”1 This review
elegantly outlined the problem of insulin insufficiency
resulting from the autoimmune destruction of beta cells in
type 1 diabetes (T1D) and the challenges and potential solu-
tions in addressing such a problem. The review focused on
the biological replacement of insulin through transplantation
of beta cell-like clusters and possibly other endocrine cells
derived from stem cells in vitro. It highlighted the latest
achievements in producing such glucose responsive “islets”
in an efficient and reproducible manner. The advent of pro-
ducing fully functional stem cell-derived islets is undoubt-
edly exciting and encouraging for the treatment of T1D and,
possibly, type 2 diabetes (T2D), through transplantation. The
review also addressed the critical shortage of pancreatic
islets obtained from cadaveric organ donors for clinical
transplantation. Although there is room for further refine-
ment, stem cells provide a virtually limitless source of uni-
form supply of insulin-producing cells for clinical
transplantation and research applications.
The review also asserted that addressing the islet supply
challenge is only half of the solution, as mitigating the
immune responses against transplanted islets remains a sig-
nificant challenge, despite substantial advancements in
immune therapies. Notably, protecting the transplanted islets
from both allogeneic (allo) and autoimmune responses is
required in the diabetic recipients, regardless of whether
cadaveric or stem cell-derived islets are used. Moreover,
transplanted islets derived from autologous stem cells could
also be subject to recurrent autoimmunity that caused the
recipient’s T1D. Indeed, protecting the transplanted islets
from recurrent autoimmunity may be more challenging, as
evidence has shown recurrent T1D in some transplant reci-
pients who are on continuous immune suppression adequate
to avoid allorejection2.
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The review further discussed important considerations in
islet transplant therapy to ensure its durability on the long-
term. These included (a) establishing new methods for pro-
tecting the islet graft from immune-mediated rejection and
(b) identifying the best transplant site(s) outside the pancreas
for easy access and where adequate supply of oxygen, nutri-
ents, and other trophic factors are available to the islet graft.
Consistently, several extra-pancreatic transplant sites have
been considered, such as the subcutaneous, intraperitoneal,
omental, and hepatic sites. But clinical experience in some of
them either shows limited islet survival and function (e.g.,
liver) or the clinical evidence is currently lacking to draw
conclusions about their potential utility3. Physical and bio-
logical methods for protecting the stem-cell derived islets
from immune attack were also discussed, such as, encapsu-
lation and localized or systemic immune manipulation to
evade immune recognition and clearance (e.g., through
the induction of immune anergy or specific tolerance). In
the concluding remarks, the review explicitly recognized the
above challenges as the remaining hurdles that have pre-
vented the transplant of pancreatic or stem-cell derived islets
from reaching its full therapeutic promise. The review also
advocated for the need of additional collaborative and coor-
dinated research efforts to overcome these challenges.
We agree with the conclusions of this review, namely,
that a transplant approach that can help in addressing the
challenge of a suitable transplant site while simultaneously
imparting immune protection onto the graft would be
instrumental for this promising therapeutic procedure to
reach full fruition. However, does such an “ideal” transplant
site exist in the human body? Immune privileged sites, where
immune responses are dampened, could potentially offer
such a site. However, this site should be easily accessible
without causing significant harm to the recipient. There are
several sites in the body that are immune privileged (e.g.,
testis, brain, placenta, and anterior chamber of the eye).
While the testicular site has been used in animal studies4,
clearly, not all these sites are suitable for clinical islet trans-
plant. In 2008, we introduced islet transplant in the anterior
chamber of the mouse eye to study the islet physiology in
vivo5,6. Three years later, we reported that intraocular islet
transplant is suitable for clinical application based on nonhu-
man primate studies that demonstrated its feasibility and
potential efficacy7. Since then, we have further developed
intraocular islet transplant to study immune reactions against
pancreatic islets during the development of type 1 diabetes
and following transplant8,9. Hence, we have been using
intraocular islet transplant to study various aspects of the
islet immunobiology in health and disease10–19.
Our extensive pre-clinical studies with intraocular islet
transplant have demonstrated its technical and physiological
advantages (Fig. 1). This includes enabling high-resolution
monitoring of the graft survival and function noninvasively
and longitudinally5,20, high local oxygen tension conducive
to the transplanted islets’ efficient engraftment, revascular-
ization, and reinnervation13,14,21, and allowing direct access
Figure 1. Islet transplant in the anterior chamber of the eye offers technical and physiological advantages that promote the graft survival on
the short- and long-term. Schematic depiction of the transplant of pancreatic or stem cell-derived islets into the anterior chamber of the eye
(credit: Zein M. Abdulreda and Tilo Moede).
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to the graft immediate microenvironment for diagnostic and
therapeutic purposes22–25. Our studies have also shown how
timely therapeutic interventions are facilitated by intraocular
transplant if/when needed to prevent rejection or recurrent
autoimmunity based on direct information derived from the
intraocular islet grafts, and how such interventions are fea-
sible, not only systemically, but also locally via topical
application (i.e., eye-drops). They further demonstrated that
intraocular islet grafts are reliable reporters of the autoim-
mune attack against islets in the native pancreas and extra-
pancreatic sites, and how information obtained from such
reporter islets enabled the prediction of T1D onset24 and the
transplant outcome (i.e., rejection versus tolerance) in mur-
ine models26.
Moreover, our studies demonstrated immunosuppression-
free, long-term survival of intraocular islet allografts in
mouse and nonhuman primate models27,28. These studies
provided evidence for local and peripheral immune regula-
tion consistent with donor-specific tolerance that promoted
the survival of additional islet grafts from the same donors27.
Importantly, this establishes a significant proof-of-concept
for a potential approach of sequential islet transplants,
whereby immune tolerance is induced through an initial
intraocular islet transplant followed by an additional transplant
of a curative islet dose (mass) in a preferred extra-pancreatic
site. Notably, the recent advent of stem cell-derived islets is
directly conducive to this sequential transplant approach since
it provides “identical” islets from the same source (donor) for
repeat transplants. This is significant when considering the
poor islet recovery following cryopreservation and would be
a great complementation to intraocular islet transplant in future
clinical applications.
Encouraged by our pre-clinical studies, we recently initi-
ated a pilot clinical trial to evaluate the safety and potential
efficacy of intraocular islet transplant in select T1D patients
with impaired hypoglycemia awareness and severe hypogly-
cemia (i.e., problematic hypoglycemia)29 (ClinicalTrials
.gov Identifier: NCT02846571). While we await the results
from this trial, the pre-clinical and early clinical evidence
thus far indicates that intraocular islet transplant will likely
be safe in humans and may impact significantly on diabetes,
as we previously discussed30. If, however, the human data
show that complete insulin independence is not achieved
through intraocular islet transplant alone, it is likely that the
islet mass in the anterior chamber of one or both eyes will
reduce hypoglycemic episodes consistently with previous
trials, which will significantly improve the quality-of-life
of the recipients31,32. Moreover, this could be further
addressed by the sequential transplant approach discussed
above, which is significantly facilitated by the advent of
stem cell-derived islets.
In summary, the recent review by D. Melton highlighted
the promise of stem cell-derived islets in clinical islet trans-
plant but also pointed out the remaining challenges to solve.
Using the eye anterior chamber as an islet transplant site may
overcome these challenges. The eye anterior chamber is
easily accessible, and the overwhelming evidence thus far
supports its clinical utility where many of its technical and
physiological advantages can be leveraged to promote the
survival and function of islet transplants in the long-term.
Thus, the combination of stem cell-derived islets and intrao-
cular transplant could help islet transplant therapy reach full
fruition.
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